Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma

T cells modified to express chimeric antigen receptor (CAR) targeting CD19 (CD19CAR) have produced remarkable clinical responses in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. CD19CAR T-cell therapy has also demonstrated prominent effects in B-cell non-Hodgkin lymphoma (B-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Köksal, Hakan, Dillard, Pierre, Josefsson, Sarah E., Maggadottir, Solrun Melkorka, Pollmann, Sylvie, Fåne, Anne, Blaker, Yngvild Nuvin, Beiske, Klaus, Huse, Kanutte, Kolstad, Arne, Holte, Harald, Kvalheim, Gunnar, Smeland, Erlend B., Myklebust, June H., Inderberg, Else Marit, Wälchli, Sébastien
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2019
Matèries:
Immunobiology and Immunotherapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482360/
https://ncbi.nlm.nih.gov/pubmed/30979721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018029678
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars